NEW YORK, April 14, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of U.S. Physical Therapy, Inc. securities (NYSE:USPH) from May 8, 2014 through March 16, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for U.S. Physical Therapy investors under the federal securities laws.
To join the U.S. Physical Therapy class action, go to http://rosenlegal.com/cases-1088.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) U.S. Physical Therapy had a material weakness in its internal controls over accounting and financial reporting; (2) U.S. Physical Therapy improperly accounted for redeemable non-controlling interests of acquired partnerships in violation of Generally Accepted Accounting Principles; (3) U.S. Physical Therapy’s financial statements for the years ended December 31, 2015 and 2014, and all quarters within 2014 and 2015, and the first three quarters of 2016 contained material errors; and (4) as a result, defendants’ statements about U.S. Physical Therapy’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 30, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1088.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 



